Glutathione Administration Guidelines
Introduction to Glutathione Administration
- The available medical literature addresses glutathione through oral, intravenous, and topical routes only, with no discussion on subcutaneous administration in any guideline or high-quality research 1, 2, 3, 4, 5
Evidence-Based Dosing by Route
- For pediatric parenteral nutrition, N-acetylcysteine (NAC) 20-50 mg/kg/day has been used to increase blood glutathione levels, as recommended by Clinical Nutrition 2
- NAC may be considered for methemoglobinemia when methylene blue is contraindicated, though dosing is not standardized, according to the American Journal of Hematology 5
Critical Safety Considerations
- No pharmacokinetic data exists for subcutaneous bioavailability of glutathione, posing significant risks 2
- Subcutaneous administration of glutathione carries risks of injection site reactions, tissue irritation, or abscess formation 5
- Unknown absorption rates and systemic effects are associated with subcutaneous glutathione administration 1
- There is a lack of sterile, pharmaceutical-grade formulations designed for subcutaneous use of glutathione 5
Clinical Recommendation
- N-acetylcysteine 20-50 mg/kg/day may be considered as a glutathione precursor for patients requiring parenteral supplementation, as suggested by Clinical Nutrition 2
Glutathione Contraindications and Safety Considerations
Clinical Context-Specific Considerations
- The American Society of Clinical Oncology suggests that glutathione should NOT be used for preventing taxane-induced peripheral neuropathy, as a large placebo-controlled trial of 185 patients receiving paclitaxel/carboplatin demonstrated no benefit, indicating that GSH is ineffective against taxane-induced neuropathy 6
- For platinum-based chemotherapy neuropathy prevention, the evidence is mixed, with five small trials showing statistically significant reductions in neurotoxicity with GSH (1.5-2.5g IV) before cisplatin or oxaliplatin, primarily demonstrated with cisplatin and oxaliplatin, not carboplatin, according to the Journal of Clinical Oncology 6, 7
Population-Specific Considerations
- The European Society for Clinical Nutrition and Metabolism, the European Society for Paediatric Gastroenterology, Hepatology and Nutrition, and the European Cystic Fibrosis Society recommend that there are no data supporting the use of glutathione therapy in CF patients, and supplementation is not recommended 8
Safe Dosing of Glutathione
Intravenous/Parenteral Administration
- The American Society for Parenteral and Enteral Nutrition recommends 20-50 mg/kg/day of N-acetylcysteine (NAC) for increasing blood glutathione levels in pediatric parenteral nutrition, as NAC serves as a precursor that cells can use to synthesize glutathione 9
- The Clinical Nutrition society suggests 0.2-0.4 g/kg/day of L-glutamine (or 0.3-0.6 g/kg/day alanyl-glutamine dipeptide) for ICU patients requiring parenteral nutrition 10
Common Pitfalls to Avoid
- The Clinical Nutrition society emphasizes the importance of not confusing glutathione with glutamine—they are different compounds with different indications 10
Intravenous Glutathione Dosing for Chemotherapy‑Induced Neuropathy
Maximum Single Dose Studied
- The highest intravenous glutathione dose evaluated in clinical trials is 2.5 g administered as a single infusion immediately before chemotherapy (Journal of Clinical Oncology, 2014) – evidence from a controlled trial. 11
Dose Range per Administration
- Clinical studies have used an intravenous dose range of 1.5–2.5 g per administration.
- 1.5 g/m² body‑surface area (approximately 2.5–4 g for average adults) was employed in several platinum‑based chemotherapy neuropathy‑prevention trials, infused over 15 minutes immediately prior to the chemotherapy session. (Journal of Clinical Oncology, 2014) – Level II evidence. 11
- The 2.5 g total dose over 15 minutes represents the maximum single dose examined in the Bogliun 1996 trial for cisplatin‑induced neuropathy. (Journal of Clinical Oncology, 2014) – Level II evidence. 11
Administration Frequency
- In the cited studies, glutathione was given with each chemotherapy cycle (typically every 2–3 weeks), not on a daily basis. (Journal of Clinical Oncology, 2014) – Level II evidence. 11
Recommended IV Dosing Algorithm (Based on the Same Evidence)
- When parenteral administration is indicated: use 1.5 g/m² IV over 15 minutes (maximum 2.5 g per dose), administered intermittently with each chemotherapy cycle. (Journal of Clinical Oncology, 2014) – Level II evidence. 11
Intravenous Glutathione for Prevention of Platinum‑Induced Chemotherapy Neuropathy
Indications
- In patients receiving platinum‑based chemotherapy (cisplatin or oxaliplatin), intravenous glutathione can be used to lower the incidence and severity of neurotoxicity; five small randomized trials reported statistically significant reductions in neuropathy, providing moderate‑level evidence. 12
Dosage and Administration
- The recommended initial dose is 1,500 mg/m² (≈ 2.5–4 g for an average adult) diluted in 100 mL normal saline and infused over 15 minutes, administered immediately before each chemotherapy cycle (typically every 2–3 weeks). 12
- Clinical studies have evaluated single‑dose amounts ranging from 1.5 g to 2.5 g; the most frequently used regimen corresponds to 1,500 mg/m². 12
- Infusion must be performed over 15 minutes (never as a rapid bolus) to minimize the risk of infusion‑related adverse events. 12
Evidence Base
- The strongest evidence for intravenous glutathione comes from prevention of platinum‑induced neuropathy, where five small randomized trials demonstrated a statistically significant decrease in neurotoxic outcomes compared with control groups. This constitutes moderate‑quality evidence (multiple RCTs, limited sample size). 12